Fresenius Group Overview

Outlook

Group Outlook 2020

In 2020, we expect to increase Group sales1 by 4% to 7% in constant currency. We project Group net income2,3 to increase by 1% to 5% in constant currency.

  Targets 20204 Fiscal year 20195
Fresenius Group
Sales growth (in constant currency) 4% – 7% € 35,409 million
Net income2 growth
(in constant currency)
1% – 5% € 1,879 million
Fresenius Medical Care
Sales growth (in constant currency) Mid-to-high
single-digit
%-range
€ 17,477 million
Net income6 growth (in constant currency) Mid-to-high
single-digit
%-range
€ 1,236 million
Fresenius Kabi
Sales growth (organic) 3% – 6% € 6,919 million
EBIT growth (in constant currency) -4% – 0% € 1,205 million
Fresenius Helios
Sales growth (organic) 3% – 6% € 9,234 million
EBIT growth 3% – 7% € 1,025 million
Fresenius Vamed
Sales growth (organic) 4% – 7% € 2,206 million
EBIT growth 5% – 9% € 134 million

 

  • 1 Base 2019: € 35,409 million, including IFRS 16, including NxStage operations
  • 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
  • 3 Base 2019: € 1,879 million, before special items, including IFRS 16, including NxStage operations
  • 4 Before special items
  • 5 Before special items, including IFRS 16, including NxStage operations
  • 6 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
  •  
  • As of December 31, 2019